Florbetapir F 18 is used only in a medical setting:

1. You will receive the injection of the tracer by a healthcare professional.

    

2. After the injection, you wait about 30-50 minutes to allow the tracer to reach the brain.

    

3. Then you undergo a PET scan, which takes about 20 minutes.

    

4. During the scan, you lie still while the machine takes images of your brain.

    

5. After the scan, you can usually resume normal activities.

Florbetapir F 18 works by binding to amyloid plaques in the brain. After injection:

• The radioactive tracer travels through your bloodstream to the brain.

   

• It attaches specifically to amyloid plaques.

   

• During a PET scan, the tracer emits signals detected by the scanner, creating images.

   

• These images show where plaques are located and how many plaques are present.

   

This helps doctors see if a patient has abnormal amyloid buildup, which is a hallmark of Alzheimer’s disease.

Florbetapir F 18 is generally safe but may cause some side effects.

Common Side Effects:

• Mild injection site pain or redness

   

• Headache

   

• Nausea

   

Serious Side Effects (rare):

• Allergic reactions like rash, itching, or difficulty breathing

   

• Reactions related to the injection process

   

If you experience any serious reactions, tell your healthcare provider immediately.

Before having a Florbetapir F 18 scan:

• Inform your doctor if you are pregnant or breastfeeding.

   

• Tell your healthcare provider about any allergies or health conditions.

   

• Discuss any medications you are currently taking.

   

• Avoid unnecessary exposure to radiation before and after the scan.

   

• Follow any instructions given by the imaging center.

   

• Florbetapir F 18 does not have known drug interactions because it is used only for imaging.

   

• Inform your doctor about any medications you take before the scan.

   

• Pregnant or breastfeeding women should inform their doctor because radioactive agents may harm the baby.

   

• The dose is carefully calculated by the medical team based on safety standards.

   

• Injection is done only by trained healthcare professionals.

   

• Usually, only one scan is needed, but doctors may repeat it if necessary.

   

• Follow all pre- and post-scan instructions from your healthcare provider.

   

Florbetapir F 18 is not available as a medicine for home use.

• It is a diagnostic agent used only in hospitals or specialized imaging centers.

   

• A doctor’s referral or prescription is needed to have the scan.

   

• The scan is ordered by neurologists or specialists evaluating memory problems or dementia.

   

• Insurance or healthcare systems may require prior approval for the scan.

• What is Florbetapir F 18 used for?
  It is used for a PET (positron emission tomography) scan to estimate the density of β-amyloid neuritic plaques in the brain of adult patients with cognitive impairment being evaluated for Alzheimer’s disease (AD) or other causes of cognitive decline. 
  A negative scan suggests sparse to no plaques, which makes AD less likely; a positive scan indicates moderate to frequent plaques but does not by itself establish a diagnosis of AD. 

• What is the brand name?
  Amyvid® (i.e., florbetapir F 18 injection). 

• What is the active ingredient?
  Florbetapir labeled with the radionuclide Fluorine-18 (F-18) — described as florbetapir F 18. 

• How does Florbetapir F 18 work?

  • The florbetapir molecule binds to β-amyloid plaques in the brain. The attached F 18 isotope emits positrons, which are detected by a PET scanner, providing images of the plaque density. 

  • In vitro and post-mortem studies show the binding signal correlates with actual plaque deposition. 

• What type of medication is it?
  A radiopharmaceutical diagnostic agent (specifically PET imaging agent). 

• How is Florbetapir F 18 administered?

  • Given by intravenous (IV) injection, as a single dose (commonly 370 MBq/10 mCi) prior to a PET scan. 

  • Must be handled by qualified nuclear medicine professionals, under strict radiation-safety protocols.

• What forms and strengths are available?

  • Solution for injection of florbetapir F 18 (with specified radiopharmaceutical activity). 

  • No typical “tablet or capsule” forms — only the injectable radiolabeled agent.

• How long does it take to work?

  • The imaging is done approximately 30–50 minutes after injection.

  • The F 18 half-life is about 110 minutes, which allows sufficient time for distribution and imaging. 

• What are the common side effects?

  • Side-effects from injection and radiation exposure: injection-site pain, irritation; headache; nausea; feeling cold; neck-pain; fatigue. 

  • Position‐related issues during the scan (e.g., discomfort from being still) may also occur.

• Are there serious side effects or risks?

  • Because of radiation exposure, there’s an increased long-term risk of developing cancer (though small) — decision to use must weigh benefits vs risks. 

  • Allergic reactions: hives, swelling, difficulty breathing (rare).

  • Not for use in children (safety/efficacy not established). 

• Who should not receive it?

  • Pediatric patients: use in children not studied or approved. 

  • Pregnant or breastfeeding women: must weigh radiation risk; breastfeeding should be interrupted for a specified time after administration. 

  • Individuals for whom a PET scan is not medically appropriate or when the test result wouldn’t change management.

• Can it be used during pregnancy or while breastfeeding?

  • Radiation exposure to fetus is a significant concern — only use if clearly necessary and with caution.

  • For breastfeeding: recommended to pause breastfeeding for 24 hours after administration. 

• Does Florbetapir F 18 interact with other medications?

  • No major drug-drug interactions documented that impact the imaging agent’s binding, although medications affecting brain amyloid or clearance might theoretically affect imaging, but this is not routinely managed via interaction. 

  • The result of the imaging must still be interpreted in the context of other medications and patient condition.

• How should it be stored and handled?

  • Radiopharmaceutical: must follow strict requirements for radioactive materials. Use appropriate shielding, storage, licensing.

  • Should be used shortly after preparation due to radioactive decay (F-18 half-life approx. 110 minutes). 

• Is there a generic available?

  • Not in the conventional sense — florbetapir F 18 is a specialty radiopharmaceutical, brand name Amyvid is the main commercial product.

  • Equivalent or alternative tracers may exist but not “generic” copies of agent.

• Where is it used?

  • In nuclear medicine facilities/cardiology or neurology departments equipped for PET imaging.

  • As part of the diagnostic evaluation of adult patients with cognitive impairment where amyloid imaging is clinically indicated.